Euroapi Company Header Euroapi Company Header

X
[{"orgOrder":0,"company":"Exelead","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exelead Inks deal to Manufacture Lipid Nanoparticles for Pfizer\/bio N Tech Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Exelead","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$780.0 million","upfrontCash":"$780.0 million","newsHeadline":"Definitive Agreement to Acquire Exelead will Strengthen Merck\u2019s CDMO Offering for mRNA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Exelead

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Exelead specializes in complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery technology which is key in mRNA-based vaccines for use in Covid-19 and many other indications.

            Lead Product(s): mRNA-based Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Merck Group

            Deal Size: $780.0 million Upfront Cash: $780.0 million

            Deal Type: Acquisition January 06, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Exelead, has delivered its first vaccine precursor batch manufactured at its facility, as part of an agreement with Pfizer for the Pfizer-BioNTech COVID-19 Vaccine, BNT162b2.

            Lead Product(s): Tozinameran

            Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162b2

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 10, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY